SpotitEarly's Dogs & AI to Revolutionize Cancer Detection in 2025
SpotitEarly, a pioneering biotech company, is set to revolutionise cancer detection. The US and Israel-based firm, led by CEO Shlomi Madar, combines specially trained dogs and artificial intelligence to sniff out cancer at its earliest stages. Their groundbreaking method, focusing initially on breast cancer, is set to launch in 2025 in partnership with Hackensack Meridian Health in New Jersey.
SpotitEarly's innovative approach hinges on dogs' keen sense of smell. These canines, primarily beagles, are trained to detect volatile organic compounds (VOCs) associated with cancer tumours. A study has demonstrated the potential of dogs combined with AI in effective early cancer detection.
Dr. Elias Obeid, medical director of the Hackensack Meridian Health Hennessy Institute, welcomes this partnership. Early detection, he notes, paves the way for less aggressive therapies and better clinical outcomes. Madar, PhD, CEO of SpotitEarly, has shared insights into the training of these remarkable cancer-sniffing dogs in a video.
SpotitEarly's groundbreaking method, in collaboration with Hackensack Meridian Health, promises to transform cancer detection. By harnessing dogs' exceptional sense of smell and AI, the company aims to detect cancer early, enabling effective treatment and potentially saving lives.
